Sir David Lane | |
|---|---|
| Born | David Philip Lane (1952-07-01)1 July 1952 (age 73)[2] Wimbledon, London, England |
| Alma mater | |
| Known for | Discovery of p53 |
| Awards | Paul Ehrlich and Ludwig Darmstaedter Prize(1998) |
| Scientific career | |
| Fields | immunology |
| Institutions | |
| Doctoral students | Sara Mole[1] |
 | Thisbiography of a living personneeds additionalcitations forverification. Please help by addingreliable sources.Contentious material about living persons that is unsourced orpoorly sourcedmust be removed immediately from the article and its talk page, especially if potentiallylibelous. Find sources: "David Lane" biologist – news ·newspapers ·books ·scholar ·JSTOR(May 2022) (Learn how and when to remove this message) |
Sir David Philip Lane (born 1 July 1952) is a Britishimmunologist,molecular biologist andcancer researcher. He is currently working in the Department of Microbiology, Tumor and Cell Biology at theKarolinska Institute and isChairman of Chugai Pharmabody. He is best known for the discovery ofp53, one of the most important tumour suppressor genes.[3]
Lane attendedThe John Fisher School in Purley, South London. He completed his undergraduate and postgraduate degrees atUniversity College, London where he studied auto-immunity under the supervision ofAvrion Mitchison.
Lane carried outpostdoctoral research first at theImperial Cancer Research Fund (ICRF) in London withLionel Crawford and then at theCold Spring Harbor Laboratory in New York withJoseph Sambrook. On returning to the UK, Lane set up his own laboratory withCancer Research Campaign (CRC) funding atImperial College, London, then moving to the ICRF laboratories at Clare Hall before moving in 1990 to the University of Dundee to help establish the CRC laboratories there.
He has played an active part in UK science, sitting at various times on the scientific committee of the CRC, the Cell Board of the MRC, and on the council of the ICRF. He is dedicated to the successful translation of research for patient benefit and participated in the early discussions around the scientific benefits of the merger of ICRF and CRC, before serving as chief scientist to their successor,Cancer Research UK, until 2010.[citation needed]
Lane founded the Dundee-based Biotechnology company,Cyclacel Ltd and was the chief scientific officer from 1996 to 2004. From 2004 to 2007, he was the executive director of the Institute of Molecular & Cell Biology (IMCB) in Singapore.[citation needed]
Sir David was chief scientist of Singapore's Agency for Science, Technology and Research (A*STAR, Singapore). He is also professor of tumour suppressor biology at the Department of Microbiology, Tumor and Cell Biology at theKarolinska Institute, where he is headinga research group.
Lane has published more than 350 research articles that have beencited over 100,000 times and is internationally recognised for his original discovery of thep53 protein SV40 T antigen complex and for his many subsequent contributions to the p53 field. The p53 gene is the most frequently altered gene in human cancer with more than half of all cancers having mutant p53. He is co-author with Ed Harlow of the most successful practical guide to the use of immunochemical methods. The "Antibodies" manual has sold over 40,000 copies.[citation needed]
Lane is a member of theEuropean Molecular Biology Organization (EMBO), and in 1996 was elected aFellow of the Royal Society, the UK's premier Academy. He is also aFellow of the Royal Society of Edinburgh, theRoyal College of Pathologists, theRoyal College of Surgeons of Edinburgh and a founder member of theAcademy of Medical Sciences.
He has won many international prizes for his work including theJoseph Steiner Prize, theMeyenburg Prize (1995), theYvette Mayent Prize, thePaul Ehrlich Prize and the Cancer Research UK Lifetime Achievement Prize (2012).[4] He has been awarded honorary degrees from the Universities of Toulouse, Birmingham, Aberdeen, Stirling, Abertay, Brno and Nottingham. He has also been recognized for his business acumen with the award of Emerging Entrepreneur of the year.
On 29 September 2016,The John Fisher School opened the Sir David Lane building.[5] In 2018, he became a laureate of theAsian Scientist 100 by theAsian Scientist.[6]
He was knighted for his contribution to cancer research in the New Year honours list in January 2000.
